Actively Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Led by Peking University First Hospital · Updated on 2025-07-30
1128
Participants Needed
6
Research Sites
294 weeks
Total Duration
On this page
Sponsors
P
Peking University First Hospital
Lead Sponsor
B
Beijing Tsinghua Chang Gung Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
CONDITIONS
Official Title
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50 years or older and less than 90 years
- Diagnosis of non-muscle-invasive bladder cancer (Ta-T1 stage)
- Scheduled for transurethral resection of bladder tumor surgery
- Agree to participate and provide written informed consent
You will not qualify if you...
- Refusal to participate
- Emergency surgery
- Presence of other malignant tumors
- Use of benzodiazepines for one week within the last month before surgery
- History of schizophrenia, epilepsy, parkinsonism, or myasthenia gravis
- Unable to communicate before surgery due to coma, severe dementia, language barrier, or end-stage disease
- Critical illness with ASA physical status IV or higher
- Severe liver dysfunction (Child-Pugh class C)
- Severe kidney dysfunction requiring dialysis before surgery
- Surgery planned only for diagnosis or if tumor removal is not possible
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Beijing Tsinghua Chang Gung Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
2
The Sixth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Peking University First Hospital
Beijin, Bejing, China, 100034
Actively Recruiting
4
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Actively Recruiting
5
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
Actively Recruiting
6
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
W
Wang Dong-Xin, MD, PhD
CONTACT
Z
Zhang Yu-Xiu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here